Bellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued to investors on Saturday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of Bellerophon Therapeutics stock opened at $0.04 on Friday. The business’s fifty day simple moving average is $0.04 and its 200-day simple moving average is $0.05. The firm has a market cap of $452,510.00, a PE ratio of -0.04 and a beta of 0.71. Bellerophon Therapeutics has a 52 week low of $0.03 and a 52 week high of $0.10.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.